The prognostic significance of the results of genotyping human immunodeficiency virus isolated from the patients with primary HIV-infection in 2009 and 2011 in St. Petersburg

Musatov, Vladimir B.; Yakovlev, Alexey A.; Tirgina, Tatiana V.; Ladnaya, Natalia N.
March 2013
Vestnik Sankt-Peterburgskogo universiteta, Seriia 7: Geologia, G;2013, Issue 1, p251
Academic Journal
The data on the subtype human immunodeficiency virus, detection rate of primary and secondary mutations in human immunodeficiency virus isolated from patients with primary HIV infection in 2009 and 2011 are presented. 78 samples were investigated. The subtype A virus prevails, which was diagnosed in 89.7%. For the first time in St. Petersburg the transfer of primary drug-resistant strains of HIV patients receiving antiretroviral therapy was described. It shows that the most frequent resistance mutations were mutations in the reverse transcriptase A62V (8 cases) and protease gene L10I/V/F/R/Y (9 cases). The analysis identifies resistance mutations and mutations polymorphisms to determine their significance in order to adopt optimal antiretroviral therapy.


Related Articles

  • Should Patients with Drug-Resistant HIV-1 Continue to Receive Antiretroviral Therapy? Frenkel, Lisa M.; Mullins, James I. // New England Journal of Medicine;02/15/2001, Vol. 344 Issue 7, p520 

    Editorial. Discusses a study published in the February 15, 2001 issue of the 'New England Journal of Medicine' which demonstrates that among HIV-1 patients with incomplete suppression of viral replication, HIV-1 plasma levels may be significantly lower with antiretroviral than if it were...

  • Evolution and viral characteristics of a long-term circulating resistant HIV-1 strain in a cluster of treatment-naive patients. Hofstra, L. Marije; Nijhuis, Monique; Pingen, Marieke; Mudrikova, Tania; Riezebos-Brilman, Annelies; Simoons-Smit, Alberdina M.; Van Ham, Petra M.; Bierman, Wouter F. W.; Wensing, Annemarie M. J. // Journal of Antimicrobial Chemotherapy (JAC);Jun2013, Vol. 68 Issue 6, p1246 

    Background Transmitted resistant HIV may revert to wild-type in the absence of drug pressure due to reduced replication capacity (RC). We observed eight therapy-naive patients infected with HIV harbouring four mutations at nucleoside reverse transcriptase inhibitor (NRTI) resistance-related...

  • US HIV group spends 25% of time with viral load above 1500 copies.  // HIV Treatment ALERTS!;Sep2015, p23 

    The article discusses the time spent by U.S. patients with human immunodeficiency virus (HIV) with viral load in receiving care. Topics covered include the importance of viral load to the transmission of the virus to other people. Also mentioned is the percentage of people who are receiving...

  • Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis. Grant, Robert M.; Liegler, Teri // Journal of Infectious Diseases;4/15/2015, Vol. 211 Issue 8, p1202 

    The author reflects on the evaluation of risk of drug resistance associated with antiretroviral therapy to control the human immunodeficiency virus (HIV) epidemic with the benefits of preexposure prophylaxis (PrEP). It mentions advantages of antiretroviral therapy observed in African populations...

  • Transmission of HIV-1 Drug-Resistant Variants: Prevalence and Effect on Treatment Outcome. Jakobsen, Martin R.; Tolstrup, Martin; Søgaard, Ole S.; Jørgensen, Louise B.; Gorry, Paul R.; Laursen, Alex; Østergaard, Lars // Clinical Infectious Diseases;2/15/2010, Vol. 50 Issue 4, p566 

    Background. Human immunodeficiency virus type 1 (HIV-1) drug resistance is an important threat to the overall success of antiretroviral therapy (ART). Because of the limited sensitivity of commercial assays, transmitted drug resistance (TDR) may be underestimated; thus, the effect that TDR has...

  • QTC interval prolongation in HIV-negative versus HIV-positive subjects with or without antiretroviral drugs. Ogunmola, Olarinde Jeffrey; Oladosu, Yusuf O.; Olamoyegun, Michael A. // Annals of African Medicine;Dec2015, Vol. 14 Issue 4, p169 

    Background: QTc interval prolongation signifies an increased risk of life-threatening arrhythmia and sudden cardiac death. Cardiac manifestations of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome have become increasingly important causes of morbidity and mortality. We...

  • Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - A preliminary report. Ghate, Manisha; Tripathy, Srikanth; Gangakhedkar, Raman; Thakar, Madhuri; Bhattacharya, Jayanta; Choudhury, Ipsita; Risbud, Arun; Bembalkar, Shilpa; Kadam, Dileep; Rewari, Bharat B.; Paranjape, Ramesh // Indian Journal of Medical Research;May2013, Vol. 137 Issue 5, p942 

    Background & objectives: The treatment outcomes under national antiretroviral therapy (ART) programme are being evaluated in some ART centres in the country. We carried out this study to analyze the impact of first line antiretroviral therapy in HIV infected patients attending a free ART roll...

  • Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. Curran, Adrian; Gutirerrez, Mar; Deig, Elisabet; Mateo, Gracia; Lopez, Rosa Maria; Imaz, Arkaitz; Crespo, Manuel; Ocaña, Inma; Domingo, Pere; Ribera, Esteban // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2195 

    Objectives: To evaluate the virological efficacy, safety, tolerability and pharmacokinetics of a regimen containing 900/100 mg of ritonavir-boosted darunavir once daily in patients with antiretroviral experience but no darunavir resistance.

  • IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy—results from the ANRS CO4 cohort. Fontas, Eric; Kousignian, Isabelle; Pradier, Christian; Poizot-Martin, Isabelle; Durier, Christine; Weiss, Laurence; Levy, Yves; Costagliola, Dominique // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2215 

    Objectives: We investigated why, despite its beneficial effect on the CD4 cell count, IL-2 therapy had no clinical benefit as shown in the ESPRIT and SILCAAT trials. We focused on subgroups of patients defined according to CD4 cell counts at baseline and over time to assess the threshold above...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics